Ketamine for Anxiety: What the research shows

If you’re reading this, there’s a good chance you’ve been on a long treatment journey already. Many people who struggle with anxiety have tried multiple treamtents: SSRIs, benzodiazepines, therapy modalities, lifestyle changes, or some combination of all of the above — often with partial relief at best. That process can be exhausting, discouraging, and at times demoralizing.

Anxiety affects an estimated 42 million Americans, making it the most common mental health condition in the United States. In recent years, ketamine has emerged as a novel potential treatment option that works very differently from traditional anxiety medications. While ketamine is best known for its strong evidence in treating depression, growing research suggests it may also play a meaningful role in reducing anxiety symptoms, particularly when anxiety co-occurs with depression.

This article reviews what the research currently shows about ketamine for anxiety, how it works, who may benefit most, and how to think about next steps. It also addresses safety, side effects, and how ketamine fits into a comprehensive mental health plan.

Ketamine for anxiety or depression are off-label uses and are not FDA-approved for these indications. Treatment should only be provided under the supervision of a qualified medical provider following a thorough evaluation.

‍

The Connection Between Anxiety and Depression

Anxiety and depression are often discussed as separate conditions, but clinically they overlap far more than most people realize. Research shows that more than 50% of individuals with major depressive disorder (MDD) also meet criteria for an anxiety disorder. This combination is often referred to as anxious depression.

At Ember Health, this overlap is even more pronounced: approximately 75% of Ember patients experience significant anxiety alongside depression. Rather than being an exception, anxious depression is the norm for many people seeking care.

This distinction matters because the strongest evidence for ketamine’s anxiety-reducing effects comes specifically from this population. A landmark study published in The Journal of Clinical Psychiatry found that individuals with anxious depression showed robust and sustained antidepressant responses to ketamine, comparable to, and in some cases stronger than, those without prominent anxiety symptoms. Importantly, anxiety did not blunt ketamine’s effectiveness; it appeared to coexist with positive outcomes.

For patients who have long felt that anxiety complicates or undermines their treatment response, this finding can be validating. Rather than disqualifying someone from ketamine treatment, the presence of anxiety alongside depression may actually indicate a particularly strong fit.

In other words, if anxiety and depression are tightly linked for you, that combination may place you squarely within the population ketamine has been studied in most extensively.

‍

What Research Says About Ketamine for Anxiety

The scientific evidence for ketamine varies depending on whether it’s being studied for depression or for anxiety alone. Understanding this distinction is key to setting realistic expectations.

Evidence is Well-Established for Ketamine for Depression

Ketamine is widely considered the most studied drug to treat depression in the past 30 years. In individuals with treatment-resistant depression (TRD), multiple studies demonstrate response rates of approximately 75%, often within hours or days rather than weeks. These findings have been replicated across controlled trials, real-world clinical settings, and large observational datasets.

Because anxiety so frequently co-occurs with depression, much of what we know about ketamine’s effects on anxiety comes from this broader depression research base.

Evidence is Emerging for Ketamine for Anxiety Specifically

When ketamine is studied for anxiety as a primary diagnosis, the evidence is more limited, though promising. Early studies suggest that IV ketamine may reduce symptoms of generalized anxiety disorder, social anxiety disorder, and panic disorder, particularly in individuals who have not responded to standard treatments.

A systematic review published in Therapeutic Advances in Psychopharmacology identified only six controlled clinical trials examining ketamine for anxiety disorders. While the sample sizes were small, results consistently pointed toward short-term symptom reduction.

Additional reviews and real-world studies — including those published in CNS Spectrums, The British Journal of Clinical Pharmacology, and The Journal of Affective Disorders — support the conclusion that ketamine shows potential benefit for refractory anxiety, though larger and longer-term studies are still needed.

From this collective research, we know that IV ketamine has strong evidence for depression and anxious depression. We’re still learning how durable and predictable benefits are for anxiety alone, without depression.

‍

How Ketamine Works Differently Than Traditional Anxiety Medications

Most conventional anxiety medications target the serotonin system. SSRIs, SNRIs, and related drugs aim to gradually modulate mood and anxiety by altering serotonin signaling, a process that often takes weeks and doesn’t work for everyone.

‍

Ketamine works through an entirely different mechanism. It acts on the glutamate system, specifically the NMDA receptor, which plays a central role in learning, memory, and neural flexibility. By influencing glutamate signaling, ketamine can rapidly change how networks in the brain communicate.

Clinically, many patients describe this effect as the ability to “snap anxious thought loops.” Persistent worries, ruminations, and fear-based patterns often feel less rigid. Patients may find themselves able to reframe worries, fears, and anxiety triggers, or to view them from a more spacious, less reactive perspective. These shifts can prompt meaningful changes in thought patterns and emotional responses.

Route of administration matters. Research and clinical data of ketamine for anxious depression suggest approximate response rates of:

• IV ketamine: ~75% (source)
  
• IM ketamine: ~50% (source)
• Intranasal ketamine: ~40% (source)
• Oral ketamine: ~20% (source)
  

Ember Health exclusively provides IV ketamine, which has the strongest data and efficacity, allows for precise dosing, consistent blood levels, and real-time clinical monitoring, all of which are particularly important for patients with significant anxiety. Our emphasis on a calming, emotionally supportive session is also critical for patients navigating anxious depression, and at Ember Health, we place an emphasis on all the experiential elements of care - from music to lighting - to ensure feelings of safety.

‍

How Ketamine Unlocks Engagement with Other Tools

Ketamine is not best viewed as a standalone solution. One of its most important benefits is creating a window of opportunity.

IV ketamine can relieve underlying depression while also promoting neuroplasticity: the brain’s ability to form new connections. During this neuroplastic window, many patients find it easier to engage with tools such as CBT, DBT, breathwork, and other therapeutic practices that have previously felt inaccessible or ineffective.

This period can be a prime opportunity for behavioral change. Insights gained during treatment are often more actionable, and emotional flexibility may be temporarily increased.

At Ember, ketamine treatment is intentionally paired with education and guidance to help patients take advantage of this neuroplastic window. The goal is not just symptom reduction, but lasting change supported by skills, therapy, and ongoing care.

‍

Safety, Side Effects, and What to Expect of Ketamine for Anxiety

Concerns about safety and dissociation are common and understandable.

Common Effects During Treatment

During an infusion, patients experience an altered state of consciousness, sometimes called temporary dissociation, often described as dreamlike or feeling disconnected from the body or surroundings. This effect typically resolves during a treatment visit, and patients are under our care and monitoring for the entirety of the altered state. Many patients find the experience neutral or even calming when properly prepared, and only 5% of visits are described as psychologically difficult.

Therapeutic vs. Recreational Context

Ketamine’s reputation as a “party drug” creates understandable stigma. Therapeutic ketamine differs fundamentally from recreational use in dose, route, setting, medical supervision, and intent. Clinical treatments are carefully titrated, monitored, and designed to support psychological safety.

Ember’s Care Protocols for Anxious Patients

Ember employs multiple safeguards specifically for patients with anxiety:

• Careful screening, with particular attention to anxious depression versus anxiety alone
  
• Psychological preparation, including intention setting, aromatherapy, and breathwork
  
• 1:1 clinician monitoring throughout the duration of each infusion
  
• Clinicians trained in therapeutic communication, especially for anxious responses
  
  

It’s also important to clarify that the FDA warning issued in October 2023 applies to unsupervised oral or intranasal ketamine, not to medically supervised IV ketamine administered in a clinical setting.

‍

Is Ketamine Right for Your Anxiety?

Ketamine is not a universal solution, and honest self-assessment matters.

Strongest candidates tend to include:

• Individuals with anxiety plus a diagnosis of depression
  
• Those who have tried multiple medications or therapies without sufficient relief
  
• Patients who have, or are willing to work with, a mental health provider
  
  

For individuals with anxiety without depression, ketamine may still help, but more studies are necessary to understand long-term efficacy in this group.

Ketamine is generally not appropriate for individuals with:

• A history of ketamine or substance use disorder
  
• Active mania or psychosis
  
• Certain uncontrolled cardiovascular conditions
  
  

Working With Your Existing Care Team While Using Ketamine for Anxiety

Ketamine works best within a collaborative care model. At Ember, medication management is coordinated with each patient’s existing care team whenever possible. Therapy, psychiatric care, and ketamine treatment function best as complementary approaches.

Ember partners with over 3,000 mental health providers in NYC and offers educational resources to support collaboration. A referral is not required; if your provider hasn’t recommended ketamine, Ember clinicians are available to educate and coordinate care with them directly.

About Ember Health 

Ember Health’s approach is grounded in data and experience. To date, Ember has delivered 40,000+ infusions to 2,500+ patients, with 84% experiencing meaningful relief from depressive symptoms, the majority of whom are managing anxiety alongside their depression. Ember maintains university research partnerships with institutions such as Harvard and Columbia and contributes to the world’s largest IV ketamine dataset.

Outcomes vary, not everyone responds the same way, but treatment decisions are guided by evidence, safety, and individual context.

Practical details:

• Cost: $550 per infusion
  
• Approximately 70% of patients use out-of-network benefits, with an average of 75% reimbursement
  
• Five NYC locations: Brooklyn Heights, Upper East Side, Chelsea, Williamsburg, Tribeca
  
  

Getting Started

Beginning ketamine treatment doesn’t require a long-term commitment upfront. Ember’s process is designed to be structured and low pressure:

1. Free consultation with a doctor at Ember‍
2. In office orientation and preparation visit
3. Four infusions treatments over two weeks
4. Outcome assessment
5. Maintenance planning, as appropriate
   

If you’re curious whether your presentation aligns with the research, scheduling a free consultation is the best next step.

‍

From one of our patients:

“I am incredibly grateful to have found Ember at the time that I did. My experience has changed my life in such positive ways. I am no longer as anxious, depressed or reactive as before.”

— 39-year-old female entrepreneur with long-term chronic depression and anxiety